UFP Technologies, Inc. designs and converts foams, films and plastic materials for the medical, automotive, consumer, electronic, industrial, aerospace and defense markets in the United States. The company is headquartered in Newburyport, Massachusetts.
| Revenue (TTM) | $649.51M |
| Gross Profit (TTM) | $188.01M |
| EBITDA | $120.00M |
| Operating Margin | 16.00% |
| Return on Equity | 17.20% |
| Return on Assets | 9.37% |
| Revenue/Share (TTM) | $84.03 |
| Book Value | $62.70 |
| Price-to-Book | 4.77 |
| Price-to-Sales (TTM) | 3.62 |
| EV/Revenue | 3.686 |
| EV/EBITDA | 23.81 |
| Quarterly Earnings Growth (YoY) | 25.10% |
| Quarterly Revenue Growth (YoY) | 11.60% |
| Shares Outstanding | $7.75M |
| Float | $7.48M |
| % Insiders | 3.81% |
| % Institutions | 123.30% |
Volatility is currently expanding
UFP Technologies NASDAQ: UFPT reported third-quarter 2026 sales growth of 11.6%, supported by broad demand across its medical technology portfolio, while management outlined continued investments in capacity, operational improvements and acquisitions heading into 2027.
UFP Technologies, Inc. ( UFPT ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Ronald Lataille - CFO, Senior VP & Treasurer Mitchell Rock - President, CEO & Director Conference Call Participants Justin Ages - CJS Securities, Inc. Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Luke Fingerson Presentation Operator Good day, and welcome to UFP Technologies' Third Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note that this event is being recorded.
NEWBURYPORT, Mass.--(BUSINESS WIRE)--UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today reported net income of $20.6 million for its third quarter ended September 30, 2026, 25.8% higher than net income of $16.4 million for the third quarter of 2025. Net sales for the quarter ended September 30, 2026 were $172.4 millio.
Investors need to pay close attention to UFPT stock based on the movements in the options market lately.
GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.
UFP Technologies NASDAQ: UFPT reported second-quarter 2026 sales growth of 15.1% to $174 million, supported by broad-based demand across its medical technology portfolio, while adjusted earnings per share rose 16.8% to a company-record $2.92.
UFP Technologies, Inc. (UFPT) Q2 2026 Earnings Call Transcript
NEWBURYPORT, Mass.--(BUSINESS WIRE)--UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today reported net income of $20.9 million for its second quarter ended June 30, 2026, 21.4% higher than net income of $17.2 million for the second quarter of 2025. Net sales for the quarter ended June 30, 2026 were $174.0 million, 15.1%.
UFP Technologies' Growth Prospects Are Great Enough To Necessitate An Upgrade
Sector rotation doesn't always mean money moving from sector to sector. In many cases, investors see capital moving from large-cap to small-cap stocks.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on UFPT and any ticker you trade — then tracks every position and per-strategy win rate.
